Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for rare disease paroxysmal ...

Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigationEXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global ...

University of Pittsburgh Medical School researchers walk us through multiple approaches they’ve tried in the past, are currently using or plan to use in the future, as well as the significant ...

North Carolina economic development officials have terminated an economic incentives agreement for Novartis Gene Therapies, which hasn’t met hiring targets tied to a package that promised up to ...

The immunotherapy combination significantly improved overall survival compared with lenvatinib or sorafenib. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...